These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32403962)

  • 21. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia.
    Kupferminc M; Rimon E; Many A; Maslovitz S; Lessing JB; Gamzu R
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):123-6. PubMed ID: 21192252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Bates SM; Greer IA; Hirsh J; Ginsberg JS
    Chest; 2004 Sep; 126(3 Suppl):627S-644S. PubMed ID: 15383488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study.
    Riyazi N; Leeda M; de Vries JI; Huijgens PC; van Geijn HP; Dekker GA
    Eur J Obstet Gynecol Reprod Biol; 1998 Sep; 80(1):49-54. PubMed ID: 9758259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage.
    Elmahashi MO; Elbareg AM; Essadi FM; Ashur BM; Adam I
    BMC Res Notes; 2014 Jan; 7():23. PubMed ID: 24405979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy (PIPSICKLE): a randomised controlled trial (study protocol).
    Afolabi BB; Babah OA; Adeyemo TA; Odukoya OO; Ezeaka CV; Nwaiwu O; Oshodi YA; Ogunnaike BA
    BMJ Open; 2021 Aug; 11(8):e047949. PubMed ID: 34389570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
    Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
    Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials.
    Rodger MA; Gris JC; de Vries JIP; Martinelli I; Rey É; Schleussner E; Middeldorp S; Kaaja R; Langlois NJ; Ramsay T; Mallick R; Bates SM; Abheiden CNH; Perna A; Petroff D; de Jong P; van Hoorn ME; Bezemer PD; Mayhew AD;
    Lancet; 2016 Nov; 388(10060):2629-2641. PubMed ID: 27720497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-molecular-weight heparin in addition to low-dose aspirin for preventing preeclampsia and its complications: A systematic review and meta-analysis.
    Zheng L; Xia B; Yuan Y; Wang Y; Wang Y
    Front Cardiovasc Med; 2022; 9():1073148. PubMed ID: 36568564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined hereditary thrombophilias are responsible for poor placental vascularization development and low molecular weight heparins (LMWH) prevent adverse pregnancy outcomes in these patients.
    Gojnic MG; Dugalic SV; Stefanovic AO; Stefanovic KV; Petronijevic MA; Vrzic Petronijevic SM; Pantic IV; Perovic MD; Vasiljevic BI; Milincic NM; Zaric MM; Todorovic JS; Macura M
    J Matern Fetal Neonatal Med; 2022 Nov; 35(22):4346-4353. PubMed ID: 33207979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The preventive effect of low-dose aspirin in a PPAR-γ antagonist treated mouse model of preeclampsia.
    Guo Y; Zhu Y; Sun Y; Yang H
    BMC Pregnancy Childbirth; 2022 Jul; 22(1):606. PubMed ID: 35906540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation.
    Karadağ C; Akar B; Gönenç G; Aslancan R; Yılmaz N; Çalışkan E
    J Matern Fetal Neonatal Med; 2020 Jun; 33(11):1934-1939. PubMed ID: 31550962
    [No Abstract]   [Full Text] [Related]  

  • 32. Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction.
    McLaughlin K; Hobson SR; Chandran AR; Agrawal S; Windrim RC; Parks WT; Bowman AW; Sovio U; Smith GC; Kingdom JC
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1145-S1156.e1. PubMed ID: 34461078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of L-arginine supplementation in pregnant women with chronic hypertension and previous placenta vascular disorders receiving Aspirin prophylaxis: a randomized control trial.
    Monari F; Menichini D; Pignatti L; Basile L; Facchinetti F; Neri I
    Minerva Obstet Gynecol; 2021 Dec; 73(6):782-789. PubMed ID: 33978350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor.
    Yinon Y; Ben Meir E; Margolis L; Lipitz S; Schiff E; Mazaki-Tovi S; Simchen MJ
    Placenta; 2015 Feb; 36(2):121-4. PubMed ID: 25555501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LMWH to prevent placenta-mediated pregnancy complications: an update.
    Duffett L; Rodger M
    Br J Haematol; 2015 Mar; 168(5):619-38. PubMed ID: 25399526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticardiolipin Positivity Is Highly Associated With Intrauterine Growth Restriction in Women With Antiphospholipid Syndrome.
    Xi F; Cai Y; Lv M; Jiang Y; Zhou F; Chen Y; Jiang L; Luo Q
    Clin Appl Thromb Hemost; 2020; 26():1076029620974455. PubMed ID: 33296221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Impact of Inherited Thrombophilia Types and Low Molecular Weight Heparin Treatment on Pregnancy Complications in Women with Previous Adverse Outcome.
    Aracic N; Roje D; Jakus IA; Bakotin M; Stefanovic V
    Yonsei Med J; 2016 Sep; 57(5):1230-5. PubMed ID: 27401656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding and Preventing Placenta-Mediated Pregnancy Complications.
    Skeith L; Blondon M; Ní Áinle F
    Hamostaseologie; 2020 Aug; 40(3):356-363. PubMed ID: 32726830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects.
    Becker R; Keller T; Kiesewetter H; Fangerau H; Bittner U
    Arch Gynecol Obstet; 2013 Jul; 288(1):41-8. PubMed ID: 23389246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.